Novo Nordisk’s AM833 shows early success in obesity trials
The firm is ‘encouraged’ by the performance of the drug, both as monotherapy and in combination with semaglutide
Read More
Tag: subcutaneous amylin analogue
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
